A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

NCT05104905 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly accumulating in another ongoing study, sponsor considered that RENACOL study is no longer needed to assess the safety profile of bexmarilimab

Conditions

Interventions

Sponsor

Faron Pharmaceuticals Ltd